M Fernández Arjona, L López Martín, L M Herranz Fernández, B Sinues Ojas, J M Campá Bortoló, J Extramiana Cameno, E López Alcina, I Povo Martín, A Budía Alba, G Ordaz Jurado, J M Osca García, M Perán Teruel, V Gimeno Argente, A Navarro Beltrán, J Benejam Gual, Y E Hernández Martínez, C González Enguita
{"title":"UroLift® 前列腺尿道提升术在西班牙的临床应用：关于治疗与尿流梗阻相关并继发于良性前列腺增生症 (BPH) 的下尿路症状的共识。","authors":"M Fernández Arjona, L López Martín, L M Herranz Fernández, B Sinues Ojas, J M Campá Bortoló, J Extramiana Cameno, E López Alcina, I Povo Martín, A Budía Alba, G Ordaz Jurado, J M Osca García, M Perán Teruel, V Gimeno Argente, A Navarro Beltrán, J Benejam Gual, Y E Hernández Martínez, C González Enguita","doi":"10.1016/j.acuroe.2024.09.004","DOIUrl":null,"url":null,"abstract":"<p><p>Benign prostatic hyperplasia (BPH) is an increasingly common pathology in the adult male. BPH increases after the age of 40-45 years, and its management consumes an enormous amount of resources. The UroLift® System is an approved technology designed to treat lower urinary tract symptoms (LUTS) secondary to BPH and is used to perform the prostatic urethral lift (PUL) procedure. Various urology specialists in Spain with experience in PUL have prepared this consensus document. Endorsed by the Spanish Urology Association, its information is based on the most recent findings. The main objective of this document is to disseminate the consensus recommendations among all professionals treating patients with LUTS/BPH. Both primary care physicians and urologists can assess and offer PUL as an effective, minimally invasive treatment.</p>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical application of the UroLift® prostatic urethral lift in Spain: consensus on the treatment of lower urinary tract symptoms associated with urinary flow obstruction and secondary to benign prostatic hyperplasia (BPH).\",\"authors\":\"M Fernández Arjona, L López Martín, L M Herranz Fernández, B Sinues Ojas, J M Campá Bortoló, J Extramiana Cameno, E López Alcina, I Povo Martín, A Budía Alba, G Ordaz Jurado, J M Osca García, M Perán Teruel, V Gimeno Argente, A Navarro Beltrán, J Benejam Gual, Y E Hernández Martínez, C González Enguita\",\"doi\":\"10.1016/j.acuroe.2024.09.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Benign prostatic hyperplasia (BPH) is an increasingly common pathology in the adult male. BPH increases after the age of 40-45 years, and its management consumes an enormous amount of resources. The UroLift® System is an approved technology designed to treat lower urinary tract symptoms (LUTS) secondary to BPH and is used to perform the prostatic urethral lift (PUL) procedure. Various urology specialists in Spain with experience in PUL have prepared this consensus document. Endorsed by the Spanish Urology Association, its information is based on the most recent findings. The main objective of this document is to disseminate the consensus recommendations among all professionals treating patients with LUTS/BPH. Both primary care physicians and urologists can assess and offer PUL as an effective, minimally invasive treatment.</p>\",\"PeriodicalId\":94291,\"journal\":{\"name\":\"Actas urologicas espanolas\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Actas urologicas espanolas\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.acuroe.2024.09.004\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Actas urologicas espanolas","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.acuroe.2024.09.004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
良性前列腺增生症（BPH）在成年男性中越来越常见。良性前列腺增生症患者在 40-45 岁后逐渐增多，其治疗耗费了大量资源。UroLift® 系统是一项已获批准的技术，用于治疗继发性良性前列腺增生症（BPH）引起的下尿路症状（LUTS），并可用于实施前列腺尿道提升术（PUL）。西班牙多位具有前列腺尿道上提术经验的泌尿科专家编写了这份共识文件。本文件由西班牙泌尿外科协会批准，其信息以最新研究成果为基础。本文件的主要目的是向所有治疗 LUTS/BPH 患者的专业人员传播共识建议。初级保健医生和泌尿科医生都可以将 PUL 作为一种有效的微创治疗方法进行评估和提供。
Clinical application of the UroLift® prostatic urethral lift in Spain: consensus on the treatment of lower urinary tract symptoms associated with urinary flow obstruction and secondary to benign prostatic hyperplasia (BPH).
Benign prostatic hyperplasia (BPH) is an increasingly common pathology in the adult male. BPH increases after the age of 40-45 years, and its management consumes an enormous amount of resources. The UroLift® System is an approved technology designed to treat lower urinary tract symptoms (LUTS) secondary to BPH and is used to perform the prostatic urethral lift (PUL) procedure. Various urology specialists in Spain with experience in PUL have prepared this consensus document. Endorsed by the Spanish Urology Association, its information is based on the most recent findings. The main objective of this document is to disseminate the consensus recommendations among all professionals treating patients with LUTS/BPH. Both primary care physicians and urologists can assess and offer PUL as an effective, minimally invasive treatment.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
